TD Cowen analyst Mathew Blackman upgraded Zimmer Biomet (ZBH) to Buy from Hold with a price target of $109, up from $99, as the analyst took over coverage of the stock. Despite what the analyst calls “very visible execution issues,” the firm sees an improving growth and profit story with room for valuation to recalibrate higher, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet says sales growth outlook for 2026 ‘tempered’
- Zimmer Biomet price target raised to $99 from $97 at Bernstein
- Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
- Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside
- Zimmer Biomet downgraded to Market Perform from Outperform at Raymond James